Skip to Content

CDC Panel Recommends Resuming Use of J&J COVID-19 Vaccine

FRIDAY, April 23, 2021 -- The United States should resume administering the Johnson & Johnson COVID-19 vaccine, a key advisory panel for the Centers for Disease Control and Prevention voted on Friday.

The agency's Advisory Committee on Immunization Practices (ACIP) has determined that the benefits of the vaccine in preventing deaths and hospitalizations far outweigh the risks of rare blood clots, risks that are mainly borne by young women.

The panel vote was 10 in favor, four opposed, and one abstention. The opposing votes favored a stronger warning for women younger than 50 that would give them the option of choosing another vaccine. The panel's recommendation comes more than a week after the CDC pressed "pause" on the rollout of the J&J vaccine. It now goes to CDC Director Rochelle Walensky for final approval.

In coming to its decision, ACIP considered a risk/benefit analysis that estimates that, for every one million doses of the Johnson & Johnson vaccine administered: 13 cases of blood clots will occur in women 18 to 49, but at the same time, 12 COVID-19-related deaths, 127 intensive care unit (ICU) admissions for COVID-19, and 657 related hospitalizations will be prevented; two cases of blood clots will occur in women 50 and older, but 593 deaths, 1,292 ICU admissions, and 4,794 hospitalizations will be prevented; two cases of blood clots will occur in men 18 to 49, but 11 COVID deaths, 114 ICU admissions, and 601 hospitalizations will be prevented; and no cases of blood clots will occur in men 50 and older, but 708 deaths, 1,485 ICU admissions, and 5,513 hospitalizations will be prevented.

The pause in use of the one-dose vaccine came after six U.S. reports, one fatal, of a rare but severe form of blood clot tied to use of the J&J shot, all occurring in women. At Friday's meeting, a CDC scientist presented nine new confirmed cases of the disorder, bringing the total to 15, The New York Times reported. All the cases have been in women, and 13 have been in women between 18 and 49 years old. Three women have died from the rare clots and seven remain hospitalized, four of whom are in the ICU, the CDC scientist said.

Joanne Waldstreicher, M.D., the chief medical officer of Johnson & Johnson, said the company has agreed with the U.S. Food and Drug Administration to add a warning label to the vaccine, which notes that "most cases" of the clotting disorder have occurred in women between 18 and 49 years old.

The New York Times Article

© 2021 HealthDay. All rights reserved.

Read this next

AI System Can Predict Deterioration in COVID-19 Patients in ED

THURSDAY, May 13, 2021 -- An artificial intelligence (AI) system can predict deterioration of COVID-19 patients in the emergency department, according to a study published online...

Pfizer Vaccine Given Final Approval for Use in Adolescents

THURSDAY, May 13, 2021 -- In a decision that clears the way for schools to reopen safely next fall, U.S. health officials on Wednesday gave their final stamp of approval for the...

Neurological Manifestations Prevalent for Inpatients With COVID-19

THURSDAY, May 13, 2021 -- Neurological manifestations are common among patients hospitalized with COVID-19 and are associated with an increased risk for in-hospital mortality,...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.